{"id":892956,"date":"2025-10-06T19:30:15","date_gmt":"2025-10-06T23:30:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\/"},"modified":"2025-10-06T19:30:15","modified_gmt":"2025-10-06T23:30:15","slug":"investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\/","title":{"rendered":"Investors who lost money on Altimmune, Inc. (ALT) should contact Levi & Korsinsky about pending Class Action – ALT"},"content":{"rendered":"
\n

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Altimmune, Inc.<\/strong> (“Altimmune” or the “Company”) (NASDAQ: ALT) of a class action securities lawsuit.<\/p>\n

\n CLASS DEFINITION: <\/strong>The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between August 10, 2023 and June 25, 2025. Follow the link below to get more information and be contacted by a member of our team:<\/p>\n

\n https:\/\/zlk.com\/pslra-1\/altimmune-inc-lawsuit-submission-form-2?prid=170642&wire=3<\/a>\n <\/p>\n

\n ALT<\/strong> investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com<\/a>\u00a0or by telephone at (212) 363-7500.<\/p>\n

\n CASE DETAILS: <\/strong>According to the complaint, on June 26, 2025, Altimmune published a press release announcing topline results from the IMPACT Phase 2b MASH trial of Pemvidutide in the Treatment of MASH. While defendants had continuously provided inflated expectations ahead of these results, the analysis showed a pointed failure by the Company to achieve statistical significance in its analysis of the fibrosis reduction primary endpoint in its IMPACT Phase 2b MASH trial. In particular, while a positive trend in fibrosis improvement was observed, statistical significance was not met due to a higher-than-expected placebo response. When questioned about this concerning miss, defendants answered indifferently, attributing this result to the Phase 2 nature of the trial and stated that Altimmune was hoping for better results following the Phase 3 trial. Following this news, the price of Altimmune\u2019s common stock declined dramatically. From a closing market price of $7.71 per share on June 25, 2025, Altimmune\u2019s stock price fell to $3.61 per share on June 26, 2025, a decline of 53.2% in the span of just a single day.<\/p>\n

\n WHAT’S NEXT? <\/strong>If you suffered a loss in Altimmune during the relevant time frame, you have until October 6, 2025<\/strong>\u00a0to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.<\/p>\n

\n NO COST TO YOU: <\/strong>If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.<\/strong><\/p>\n

\n WHY LEVI & KORSINSKY: <\/strong>Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services\u2019 Top 50 Report as one of the top securities litigation firms in the United States.<\/p>\n

\n CONTACT:<\/strong>
\n
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com<\/a>
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between August 10, 2023 and June 25, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/altimmune-inc-lawsuit-submission-form-2?prid=170642&wire=3 ALT investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, on June 26, 2025, Altimmune published a press release announcing topline results from the IMPACT Phase 2b MASH trial of … <\/p>\n

Continue reading “Investors who lost money on Altimmune, Inc. (ALT) should contact Levi & Korsinsky about pending Class Action – ALT”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-892956","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nInvestors who lost money on Altimmune, Inc. (ALT) should contact Levi & Korsinsky about pending Class Action - ALT - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Investors who lost money on Altimmune, Inc. (ALT) should contact Levi & Korsinsky about pending Class Action - ALT - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between August 10, 2023 and June 25, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/altimmune-inc-lawsuit-submission-form-2?prid=170642&wire=3 ALT investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, on June 26, 2025, Altimmune published a press release announcing topline results from the IMPACT Phase 2b MASH trial of … Continue reading "Investors who lost money on Altimmune, Inc. (ALT) should contact Levi & Korsinsky about pending Class Action – ALT"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-06T23:30:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MDAyMSM3MTc5MzU5IzIwMjA0MjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Investors who lost money on Altimmune, Inc. (ALT) should contact Levi & Korsinsky about pending Class Action – ALT\",\"datePublished\":\"2025-10-06T23:30:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\\\/\"},\"wordCount\":472,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0MDAyMSM3MTc5MzU5IzIwMjA0MjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\\\/\",\"name\":\"Investors who lost money on Altimmune, Inc. (ALT) should contact Levi & Korsinsky about pending Class Action - ALT - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0MDAyMSM3MTc5MzU5IzIwMjA0MjY=\",\"datePublished\":\"2025-10-06T23:30:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0MDAyMSM3MTc5MzU5IzIwMjA0MjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0MDAyMSM3MTc5MzU5IzIwMjA0MjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investors who lost money on Altimmune, Inc. (ALT) should contact Levi & Korsinsky about pending Class Action – ALT\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Investors who lost money on Altimmune, Inc. (ALT) should contact Levi & Korsinsky about pending Class Action - ALT - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\/","og_locale":"en_US","og_type":"article","og_title":"Investors who lost money on Altimmune, Inc. (ALT) should contact Levi & Korsinsky about pending Class Action - ALT - Market Newsdesk","og_description":"NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between August 10, 2023 and June 25, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/altimmune-inc-lawsuit-submission-form-2?prid=170642&wire=3 ALT investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, on June 26, 2025, Altimmune published a press release announcing topline results from the IMPACT Phase 2b MASH trial of … Continue reading \"Investors who lost money on Altimmune, Inc. (ALT) should contact Levi & Korsinsky about pending Class Action – ALT\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-06T23:30:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MDAyMSM3MTc5MzU5IzIwMjA0MjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Investors who lost money on Altimmune, Inc. (ALT) should contact Levi & Korsinsky about pending Class Action – ALT","datePublished":"2025-10-06T23:30:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\/"},"wordCount":472,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MDAyMSM3MTc5MzU5IzIwMjA0MjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\/","name":"Investors who lost money on Altimmune, Inc. (ALT) should contact Levi & Korsinsky about pending Class Action - ALT - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MDAyMSM3MTc5MzU5IzIwMjA0MjY=","datePublished":"2025-10-06T23:30:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MDAyMSM3MTc5MzU5IzIwMjA0MjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MDAyMSM3MTc5MzU5IzIwMjA0MjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-altimmune-inc-alt-should-contact-levi-korsinsky-about-pending-class-action-alt-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Investors who lost money on Altimmune, Inc. (ALT) should contact Levi & Korsinsky about pending Class Action – ALT"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/892956","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=892956"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/892956\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=892956"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=892956"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=892956"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}